Compare

Anixa Biosciences Inc vs Aprea Therapeutics, Inc. vs Reviva Pharmaceuticals Holdings, Inc. vs Cerenome, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearAnixa Biosciences Inc
ANIX
Aprea Therapeutics, Inc.
APRE
Reviva Pharmaceuticals Holdings, Inc.
RVPH
Cerenome, Inc.
CNSY
Year ended2025-10-312025-12-312025-12-312025-12-31
Revenuen/an/an/a$5.21M
Revenue growth (YoY)n/an/an/a-10.5%
Gross marginn/an/an/an/a
Operating marginn/an/an/a-293.5%
Net marginn/an/an/a-429.4%
Net income-$10.93M-$12.60M-$19.86M-$22.39M
EPS (Diluted)-$0.34-$1.93n/a-$0.29
Operating cash flow-$7.17M-$12.89M-$24.59M-$20.77M
Free cash flown/an/an/a-$20.84M
Cash & equivalents$1.24M$14.60M$14.44M$4.26M
Total assets$16.08M$15.93M$15.92M$16.32M
Total liabilities$2.13Mn/a$7.28M$12.33M
Shareholders' equity$15.16M$12.44M$8.65M$4.00M
Return on year-end equity-72.1%-101.3%-229.7%-560.2%
Shares outstanding33.01M8.19M5.87M138.68M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearAnixa Biosciences IncAprea Therapeutics, Inc.Reviva Pharmaceuticals Holdings, Inc.Cerenome, Inc.
Latest$210.0K
Ended 2024-10-31
n/an/a$5.21M
Ended 2025-12-31
1 year earlier$210.0K
Ended 2023-10-31
n/an/a$5.82M
Ended 2024-12-31
2 years earliern/an/an/a$4.91M
Ended 2023-12-31
3 years earlier$512.0K
Ended 2021-10-31
n/an/an/a
4 years earliern/an/an/an/a